A novel drug regimen tested for the first time by researchers at Fred Hutch Cancer Center has shown great promise in preventing moderate to severe cGVHD after transplant in people who received ...

Chronic graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT), affecting 25–66% of women. Genital GVHD is an underdiagnosed condition ...

Niktimvo, a colony stimulating factor-1 receptor-blocking antibody, was approved in 2024 for the treatment of chronic graft-vs-host disease (GVHD) after failure of at least 2 prior lines of systemic ...

Not only is it reasonably priced, but it’s lightweight, comfortable to use, and delivers a great typing experience. With multi-connectivity options and a 36-hour battery life, you also get the ...

Acute GVHD is a recognized complication of allogeneic ... of viable lymphocytes in the allograft recognizing the host HLA antigen type as foreign, resulting in a characteristic immune response.

[18] Measures to reduce GVHD risk would therefore include improvements in donor selection, improved HLA matching, as well as reduced intensity conditioning where possible. However, other trends ...

The study ricocheted around the world. Almost 200 news stories promoted the idea that we remember things better when we write them down by hand instead of typing. It confirmed what many of us ...

Ivarmacitinib sulfate is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Graft Versus Host Disease (GVHD). According to GlobalData, Phase I drugs for Graft Versus ...

Subsequently, we performed a triple knockout (tKO) of TRAC, B2M, and HLA-DRA in CD70 CAR-T cells to generate CD70 UCAR-T cells, achieving knockout efficiencies of over 80% for each gene (Figure 2B).

Axatilimab has gained FDA approval in 9 mg and 22 mg vials, expanding treatment options for patients with chronic GVHD after 2 prior therapy failures. The FDA has granted approval to axatilimab-csfr ...